Primary pulmonary extranodal natural killer/T-cell lymphoma: nasal type with multiple nodules.

REFERENCES 1 Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. 2 du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129–140. 3 Papiris SA, Manali ED, Kolilekas L, et al. Clinical review: idiopathic pulmonary fibrosis acute exacerbations – unravelling Ariadne’s thread. Crit Care 2010; 14: 246. 4 National Heart, Lung, and Blood Institute. NIH News. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. October 21, 2011. www.nih.gov/news/health/oct2011/ nhlbi-21.htm Date last accessed: January 22, 2012. 5 Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040–1047. 6 Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821–829. 7 Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769. 8 Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538–542. 9 du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382–1389. 10 Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371–383. 11 Man-Son-Hing M, Laupacis A, O’Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002; 17: 469–476.